ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB025

Secondary Membranous Nephropathy and Multifactorial AKI in a Patient with Breast Cancer

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Arefin, Mohammed Ahnaf, UT Health East Texas, Tyler, Texas, United States
  • Weyer, Alyssa Caparas, UT Health East Texas, Tyler, Texas, United States
  • Jimenez, Madeline, UT Health East Texas, Tyler, Texas, United States
Introduction

Acute kidney injury (AKI) is a common, serious complication in cancer patients. This case highlights the diagnostic challenges in evaluating AKI in an oncology patient, especially when it may result from multiple factors including medications, hemodynamic instability, infection, or paraneoplastic processes. Membranous nephropathy has been associated with cancer progression and immune checkpoint inhibitors.

Case Description

A 53-year-old female with triple-negative stage IV breast cancer and history of left upper extremity DVT presented with fever and dyspnea. CT chest revealed a partially occlusive pulmonary embolism. She was septic, hypotensive, and treated with IV vancomycin and piperacillin/tazobactam. Her baseline creatinine of 0.8 mg/dL rose to 2.0 mg/dL with subnephrotic proteinuria. She was receiving Carboplatin, Taxol, and Pembrolizumab. Nephrology was consulted for AKI. Biopsy showed acute tubular necrosis and secondary membranous nephropathy. PLA2r, THSD7A, and NELL1 antibodies were negative. The patient became anuric, required dialysis, and unfortunately did not recover renal function. She later expired.

Discussion

This case illustrates multifactorial AKI in a patient with advanced breast cancer. Despite supportive care and discontinuation of nephrotoxins, renal function declined, emphasizing the value of biopsy in unclear AKI cases. The presence of secondary membranous nephropathy raised suspicion for a paraneoplastic process. Retrospective review showed prior proteinuria, suggesting that earlier nephrologic workup may have uncovered renal involvement sooner and possibly earlier cancer detection. Timely nephrology involvement and a broad differential are crucial in oncology patients with AKI.

Digital Object Identifier (DOI)